Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Verducatib with Carbamazepine in Healthy Males
NCT07781631Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state over a uniform dosing interval at 40 days and Maximum measured concentration at steady state at 40 days. Started Sep 2026; status: recruiting.
02
Drugs
verducatib
Beyond the preview
Go deeper on NCT07781631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07781631.